Limb-girdle muscular dystrophy 2A

Handbook of Clinical Neurology

Volumn 101, Issue , 2011, Pages 97-110

  Gallardo, Eduard ^a   Saenz, Amets ^b   Illa, Isabel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CAPN3 PROTEIN, HUMAN; MUSCLE PROTEIN;

ANIMAL; BOOK; GENETICS; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MOUSE; MUTATION;

ANIMALS; CALPAIN; HUMANS; MICE; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION;

EID: 79954476376     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-08-045031-5.00006-2     Document Type: Book

References (105)

1. Amato A.A. Adults with eosinophilic myositis and calpain-3 mutations. Neurology 2008, 70:730-731.
2. Anderson L.V., Davison K., Moss J.A., et al. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. Am J Pathol 1998, 153:1169-1179.
3. Anderson L.V., Harrison R.M., Pogue R., et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000, 10:553-559.
4. Baghdiguian S., Martin M., Richard I., et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the ikappab alpha/NF-kappab pathway in limb-girdle muscular dystrophy type 2A. Nat Med 1999, 5:503-511.
5. Balci B., Aurino S., Haliloglu G., et al. Calpain-3 mutations in Turkey. Eur J Pediatr 2006, 165:293-298.
6. Bartoli M., Roudaut C., Martin S., et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 2006, 13:250-259.
7. Bartoli M., Poupiot J., Vulin A., et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 2007, 14:733-740.
8. Beckmann J.S., Bushby K.M. Advances in the molecular genetics of the limb-girdle type of autosomal recessive progressive muscular dystrophy. Curr Opin Neurol 1996, 9:389-393.
9. Beckmann J.S., Fardeau M. Limb-girdle muscular dystrophies. Neuromuscular Disorders: Clinical and Molecular Genetics 1998, 123-156. John Wiley, Chichester. A.E.H. Emery (Ed.).
10. Benayoun B., Baghdiguian S., Lajmanovich A., et al. NF-kappab-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. FASEB J 2008, 22:1521-1529.
11. Blazquez L., Azpitarte M., Saenz A., et al. Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. Neurogenetics 2008, 9:173-182.
12. Bönnemann C.G., Wong J., Ben Hamida C., et al. LGMD 2E in Tunisia is caused by a homozygous missense mutation in beta-sarcoglycan exon 3. Neuromuscul Disord 1998, 8:193-197.
13. Canki-Klain N., Milic A., Kovac B., et al. Prevalence of the 550dela mutation in calpainopathy (LGMD 2A) in Croatia. Am J Med Genet A 2004, 125:152-156.
14. Carmignac V., Salih M.A., Quijano-Roy S., et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007, 61:340-351.
15. Chae J., Minami N., Jin Y., et al. Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul Disord 2001, 11:547-555.
16. Charlton R., Henderson M., Richards J., et al. Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord 2009, 19:449-457.
17. Chrobakova T., Hermanova M., Kroupova I., et al. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mrna and their phenotypic outcome. Neuromuscul Disord 2004, 14:659-665.
18. Cohen N., Kudryashova E., Kramerova I., et al. Identification of putative in vivo substrates of calpain 3 by comparative proteomics of overexpressing transgenic and nontransgenic mice. Proteomics 2006, 6:6075-6084.
19. Daniele N., Richard I., Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 2007, 39:1608-1624.
20. Dehainault C., Michaux D., Pages-Berhouet S., et al. A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation. Eur J Hum Genet 2007, 15:473-477.
21. De Luna N., Freixas A., Gallano P., et al. Dysferlin expression in monocytes: a source of mrna for mutation analysis. Neuromuscul Disord 2007, 17:69-76.
22. De Paula F., Vainzof M., Passos-Bueno M.R., et al. Clinical variability in calpainopathy: what makes the difference?. Eur J Hum Genet 2002, 10:825-832.
23. De Paula F., Saenz A., Cobo A.M., et al. The recurrent Basque mutation in Brazilian calpainopathy patients. Am J Hum Genet 2003, 73:580.
24. De Tullio R., Stifanese R., Salamino F., et al. Characterization of a new p94-like calpain form in human lymphocytes. Biochem J 2003, 375:689-696.
25. Dincer P., Leturcq F., Richard I., et al. A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol 1997, 42:222-229.
26. Dincer P., Akcoren Z., Demir E., et al. A cross section of autosomal recessive limb-girdle muscular dystrophies in 38 families. J Med Genet 2000, 37:361-367.
27. Duno M., Sveen M.L., Schwartz M., et al. Cdna analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. Eur J Hum Genet 2008, 16:935-940.
28. Eagle M. Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord 2002, 12:975-983.
29. Fanin M., Nascimbeni A.C., Fulizio L., et al. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 2003, 163:1929-1936.
30. Fanin M., Fulizio L., Nascimbeni A.C., et al. Molecular diagnosis in LGMD2A: mutation analysis or protein testing?. Hum Mutat 2004, 24:52-62.
31. Fanin M., Nascimbeni A.C., Fulizio L., et al. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord 2005, 15:218-224.
32. Fanin M., Nascimbeni A.C., Angelini C. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations. J Med Genet 2007, 44:38-43.
33. Fanin M., Nascimbeni A.C., Tasca E., et al. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. Eur J Hum Genet 2009, 17:598-603.
34. Fardeau M., Eymard B., Mignard C., et al. Chromosome 15-linked limb-girdle muscular dystrophy: clinical phenotypes in Réunion Island and French metropolitan communities. Neuromuscul Disord 1996, 6:447-453.
35. Fardeau M., Hillaire D., Mignard C., et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Réunion Island. Brain 1996, 119:295-308.
36. Figarella-Branger D., El-Dassouki M., Saenz A., et al. Myopathy with lobulated muscle fibers: evidence for heterogeneous etiology and clinical presentation. Neuromuscul Disord 2002, 12:4-12.
37. Fischer D., Walter M.C., Kesper K., et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005, 252:538-547.
38. Fougerousse F., Gonin P., Durand M., et al. Force impairment in calpain 3-deficient mice is not correlated with mechanical disruption. Muscle Nerve 2003, 27:616-623.
39. Frischmeyer P.A., Dietz H.C. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999, 8:1893-1900.
40. Frischmeyer P.A., van Hoof A., O'Donnell K., et al. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 2002, 295:2258-2261.
41. Garvey S.M., Rajan C., Lerner A.P., et al. The muscular dystrophy with myositis (mdm) mouse mutation disrupts a skeletal muscle-specific domain of titin. Genomics 2002, 79:146-149.
42. Groen E.J., Charlton R., Barresi R., et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 2007, 130:3237-3249.
43. Guerard M.J., Sewry C.A., Dubowitz V. Lobulated fibers in neuromuscular diseases. J Neurol Sci 1985, 69:345-356.
44. Guyon J.R., Kudryashova E., Potts A., et al. Calpain 3 cleaves filamin C and regulates its ability to interact with gamma- and delta-sarcoglycans. Muscle Nerve 2003, 28:472-483.
45. Hackman P., Vihola A., Haravuori H., et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 2002, 71:492-500.
46. Hanisch F., Muller C.R., Grimm D., et al. Frequency of calpain-3 c.550dela mutation in limb girdle muscular dystrophy type 2 and isolated hyperckemia in German patients. Clin Neuropathol 2007, 26:157-163.
47. Haravuori H., Vihol A., Straub V., et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene. Neurology 2001, 56:869-877.
48. Hayashi K. PCR-SSCP: a method for detection of mutations. Genet Anal Tech Appl 1992, 9:73-79.
49. Herasse M., Ono Y., Fougerousse F., et al. Expression and functional characteristics of calpain 3 isoforms generated through tissue-specific transcriptional and posttranscriptional events. Mol Cell Biol 1999, 19:4047-4055.
50. Hermanova M., Zapletalova E., Sedlackova J., et al. Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients. Muscle Nerve 2006, 33:424-432.
51. Ho M., Gallardo E., McKenna-Yasek D., et al. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002, 51:129-133.
52. Huebsch K.A., Kudryashova E., Wooley C.M., et al. Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain. Hum Mol Genet 2005, 14:2801-2811.
53. Illa I., De Luna N., Dominguez-Perles R., et al. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology 2007, 68:1284-1289.
54. Keira Y., Noguchi S., Kurokawa R., et al. Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. Neurosci Res 2007, 57:513-521.
55. Kinbara K., Sorimachi H., Ishiura S., et al. Skeletal muscle-specific calpain, p49: structure and physiological function. Biochem Pharmacol 1998, 56:415-420.
56. Krahn M., Bernard R., Pecheux C., et al. Screening of the CAPN3 gene in patients with possible LGMD2A. Clin Genet 2006, 69:444-449.
57. Krahn M., Lopez de Munain A., Streichenberger N., et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006, 59:905-911.
58. Krahn M., Pecheux C., Chapon F., et al. Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. Clin Genet 2007, 72:582-592.
59. Kramerova I., Kudryashova E., Tidball J.G., et al. Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum Mol Genet 2004, 13:1373-1388.
60. Kramerova I., Beckmann J.S., Spencer M.J. Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). Biochim Biophys Acta 2007, 1772:128-144.
61. Kretsinger R.H. Calcium-binding proteins. Annu Rev Biochem 1976, 45:239-266.
62. Lanzillo R., Aurino S., Fanin M., et al. Early onset calpainopathy with normal non-functional calpain 3 level. Dev Med Child Neurol 2006, 48:304-306.
63. Lennon N.J., Kho A., Bacskai B.J., et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 2003, 278:50466-50473.
64. Mercuri E., Counsell S., Allsop J., et al. Selective muscle involvement on magnetic resonance imaging in autosomal dominant Emery-Dreifuss muscular dystrophy. Neuropediatrics 2002, 33:10-14.
65. Mercuri E., Bushby K., Ricci E., et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005, 15:164-171.
66. Meznaric-Petrusa M.M.P., Zidar J., Zupancic N., et al. Clinical, molecular and genetic features of calpainopathy in Slovenia. Neuromuscul Disord 2002, 12:731.
67. Milic A., Canki-Klain N. Calpainopathy (LGMD2A) in Croatia: molecular and haplotype analysis. Croat Med J 2005, 46:657-663.
68. Milic A., Daniele N., Lochmuller H., et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord 2007, 17:148-156.
69. Moore S.A., Shilling C.J., Westra S., et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol 2006, 65:995-1003.
70. Norwood F., de Visser M., Eymard B., et al. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol 2007, 14:1305-1312.
71. Ono Y., Shimada H., Sorimachi H., et al. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. J Biol Chem 1998, 273:17073-17078.
72. Passos-Bueno M.R., Vainzof M., Moreira E.S., et al. Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. Am J Med Genet 1999, 82:392-398.
73. Penisson-Besnier I., Richard I., Dubas F., et al. Pseudometabolic expression and phenotypic variability of calpain deficiency in two siblings. Muscle Nerve 1998, 21:1078-1080.
74. Piluso G., Politano L., Aurino S., et al. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005, 42:686-693.
75. Pogoda T.V., Krakhmaleva I.N., Lipatova N.A., et al. High incidence of 550dela mutation of CAPN3 in LGMD2 patients from Russia. Hum Mutat 2000, 15:295.
76. Pollitt C., Anderson L.V., Pogue R., et al. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul Disord 2001, 11:287-296.
77. Poppe M., Cree L., Bourke J., et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003, 60:1246-1251.
78. Prelle A., Sciacco M., Tancredi L., et al. Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. Acta Neuropathol 2003, 105:537-542.
79. Ravulapalli R., Diaz B.G., Campbell R.L., et al. Homodimerization of calpain 3 penta-EF-hand domain. Biochem J 2005, 388:585-591.
80. Richard I., Broux O., Allamand V., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995, 81:27-40.
81. Richard I., Brenguier L., Dincer P., et al. Multiple independent molecular etiology for limb-girdle muscular dystrophy type 2A patients from various geographical origins. Am J Hum Genet 1997, 60:1128-1138.
82. Richard I., Roudaut C., Marchand S., et al. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated ikappabalpha/nuclear factor kappab pathway perturbation in mice. J Cell Biol 2000, 151:1583-1590.
83. Saenz A., Leturcq F., Cobo A.M., et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005, 128:732-742.
84. Saenz A., Azpitarte M., Armananzas R., et al. Gene expression profiling in limb-girdle muscular dystrophy 2A. PLoS ONE 2008, 3:e3750.
85. Sorimachi H., Suzuki K. Sequence comparison among muscle-specific calpain, p94, and calpain subunits. Biochim Biophys Acta 1992, 1160:55-62.
86. Sorimachi H., Suzuki K. The structure of calpain. J Biochem (Tokyo) 2001, 129:653-664.
87. Sorimachi H., Imajoh-Ohmi S., Emori Y., et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 1989, 264:20106-20111.
88. Sorimachi H., Toyama-Sorimachi N., Saido T.C., et al. Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J Biol Chem 1993, 268:10593-10605.
89. Sorimachi H., Kinbara K., Kimura S., et al. Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995, 270:31158-31162.
90. Sorimachi H., Forsberg N.E., Lee H.J., et al. Highly conserved structure in the promoter region of the gene for muscle-specific calpain, p94. Biol Chem 1996, 377:859-864.
91. Sorimachi H., Ishiura S., Suzuki K. Structure and physiological function of calpains. Biochem J 1997, 328:721-732.
92. Sorimachi H., Ono Y., Suzuki K. Skeletal muscle-specific calpain, p94, and connectin/titin: their physiological functions and relationship to limb-girdle muscular dystrophy type 2A. Adv Exp Med Biol 2000, 481:383-395.
93. Spencer M.J., Mellgren R.L. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum Mol Genet 2002, 11:2645-2655.
94. Stehlikova K., Zapletalova E., Sedlackova J., et al. Quantitative analysis of CAPN3 transcripts in LGMD2A patients: involvement of nonsense-mediated mRNA decay. Neuromuscul Disord 2007, 17:143-147.
95. Suzuki K., Sorimachi H. A novel aspect of calpain activation. FEBS Lett 1998, 433:1-4.
96. Tagawa K., Taya C., Hayashi Y., et al. Myopathy phenotype of transgenic mice expressing active site-mutated inactive p94 skeletal muscle-specific calpain, the gene product responsible for limb girdle muscular dystrophy type 2A. Hum Mol Genet 2000, 9:1393-1402.
97. Talim B., Ognibene A., Mattioli E., et al. Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. Neurology 2001, 56:692-693.
98. Taveau M., Bourg N., Sillon G., et al. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol Cell Biol 2003, 23:9127-9135.
99. Todorova A., Georgieva B., Tournev I., et al. A large deletion and novel point mutations in the calpain 3 gene (CAPN3) in Bulgarian LGMD2A patients. Neurogenetics 2007, 8:225-229.
100. 2+-regulated phospholipid-binding domain. Biochem Biophys Res Commun 2001, 280:1333-1339.
101. Topaloglu H., Dincer P., Richard I., et al. Calpain-3 deficiency causes a mild muscular dystrophy in childhood. Neuropediatrics 1997, 28:212-216.
102. Udd B., Vihola A., Sarparanta J., et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 2005, 64:636-642.
103. Urtasun M., Saenz A., Roudaut C., et al. Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain 1998, 121:1735-1747.
104. van der Kooi A.J., Barth P.G., Busch H.F., et al. The clinical spectrum of limb girdle muscular dystrophy. A survey in The Netherlands. Brain 1996, 119:1471-1480.
105. Zatz M., de Paula F., Starling A., et al. The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2003, 13:532-544.